Policy Developments - The National Medical Insurance Administration announced that as of November 12, 2025, 24 provinces and regions in China have completed the deployment of the medical imaging cloud software, with 140 million indexed data uploaded to the national center [2] Drug and Device Approvals - Changchun High-tech's subsidiary received FDA approval for the clinical trial of GenSci143, a dual-specific antibody drug targeting B7-H3 and PSMA for treating advanced solid tumors [4] - Zai Lab announced that its ZG006 injection, in combination with etoposide and cisplatin, received clinical trial approval for advanced neuroendocrine carcinoma [5] - Heng Rui Medicine received approval for the clinical trial of Rivegromab tablets for prostate cancer [6] - Haisco announced that its HSK39297 tablets for age-related macular degeneration received clinical trial approval, showing promising preclinical results [7] Capital Market Activities - Kintor Pharmaceutical reported the repurchase of approximately 3.31 million shares since October 2025, with plans to repurchase up to 25.46 million shares over the next 50 trading days [9] - Changlian Co. signed an agreement to establish a joint venture with Shanghai Waigaoqiao Biopharmaceutical, contributing 30 million yuan for a 60% stake [10] Financial Reports - In the third quarter report, Nocera Biopharma reported a net loss of 64.41 million yuan for the first three quarters of 2025, despite a revenue increase of 59.85% to 1.115 billion yuan, driven by sales of its core product [12] Industry Events - The first China-Africa Joint Medical Center was established in Guinea, aiming to enhance healthcare collaboration and address cardiovascular diseases in West Africa [14] Shareholder Actions - Renhe Pharmaceutical's controlling shareholder plans to reduce its stake by up to 0.21% through public trading or block transactions [16]

Major Events - Guotai Group acquired 100% equity of Beikuan Baomao for 110 million yuan through public bidding [3] - People's Tongtai stock price has a risk of rapid decline after a 46.43% increase over four consecutive trading days [4] - Huasheng Lithium's revenue increased by 62% in the first three quarters, but the company still reported a loss of 102.97 million yuan [5] - Haizike received approval for clinical trials of the innovative drug HSK39297 for age-related macular degeneration [6] - Angli Education postponed its response to an asset acquisition inquiry for no more than five trading days [7] - Shuguang Co. terminated its plan to issue shares to specific targets, and the Shanghai Stock Exchange has decided to terminate the review [8] Performance Overview - JD Group reported third-quarter revenue of 299.1 billion yuan, a year-on-year increase of 14.9% [9] - SMIC's third-quarter net profit was 1.517 billion yuan, up 43.1% year-on-year [10] - Tencent Holdings achieved third-quarter revenue of 192.87 billion yuan, a 15% year-on-year growth [11] - Lu'an Huaneng's coal sales in October reached 3.78 million tons, a year-on-year increase of 3.28% [12] Shareholding Changes - Haicheng Bangda's director plans to reduce holdings by no more than 0.97% due to personal financial needs [13] - Qisheng Technology's major shareholder reduced their stake to 40% after a transaction [14] - Tianwei Electronics' major shareholder reduced their stake to below 5% [15] - Zhongzi Technology's major shareholders collectively reduced their stake by 1.35% [16] Major Contracts - Lizhong Group's subsidiary received project confirmations with an estimated total sales of approximately 1.135 billion yuan [18] - Anhui Construction's subsidiary won a project bid worth 1.753 billion yuan [19]

Company Announcements - 合富中国's stock price has significantly deviated from its fundamentals, with a cumulative increase of 230.84% over the past 13 trading days, leading to potential suspension for further investigation if abnormal price increases continue [1] - 摩尔线程 plans to conduct its initial public offering with a total of 70 million shares, representing 14.89% of the post-issue total share capital, with the initial inquiry date set for November 19 and subscription date for November 24 [2] - *ST东易's stock has risen by 241.59% since September 26, prompting a suspension for investigation starting November 14 [2] - 华蓝集团 is planning a change in company control, leading to a suspension of its stock from November 14 for up to 2 trading days [4] - 吉电股份 intends to invest 5.698 billion yuan in a coal power project with a total investment of 56.98 billion yuan, which is part of a national energy strategy [6] - 利德曼 plans to acquire 70% of 先声祥瑞 for 1.733 billion yuan, aiming to enter the bioproducts industry [6] - 佛塑科技 is collaborating with 紫金矿业 to establish a project company for a lithium sulfide pilot project with a total investment of 1.13 billion yuan [7] - 中芯国际 reported a 43% year-on-year increase in net profit for Q3, driven by increased wafer sales [8] Financing and Investments - 云南铜业 plans to increase its investment in 中铜国贸 by 640 million yuan to enhance its capital strength [11] - 德业股份 is preparing to issue H-shares and list on the Hong Kong Stock Exchange to expand its global presence [20] Shareholder Changes - 闽发铝业's second-largest shareholder, 黄天火, has reduced his stake by 938.15 million shares, representing 0.9995% of the total share capital [3] - 长联科技's shareholders plan to collectively reduce their holdings by up to 4.37% [14] Project Awards - 和顺电气 has been awarded a storage power supply service project by 中国石油集团, with a bid amount of approximately 40.003 million yuan [18] - 安徽建工's subsidiary has won two EPC projects with a total bid amount of 1.753 billion yuan [19]

Group 1: Company Performance - SMIC reported a revenue of 17.162 billion yuan in Q3 2025, a year-on-year increase of 9.9%, with a net profit of 1.51 billion yuan, up 43.1% year-on-year. For the first three quarters, revenue reached 49.51 billion yuan, growing 18.2%, and net profit was 3.81 billion yuan, an increase of 41.1% year-on-year, driven by increased wafer sales and product mix changes [1] - Huasheng Lithium reported a revenue of 538.5553 million yuan for the first three quarters of 2025, a year-on-year increase of 62.29%, but still incurred a net loss of 102.9745 million yuan [5] Group 2: Stock Performance and Risks - Aofeng China announced that its stock price has significantly deviated from its fundamentals, with a cumulative increase of 230.84% over 13 trading days, leading to potential risks for investors if the stock continues to rise abnormally [2] - Renmin Tongtai's stock experienced a cumulative increase of 46.43% over four consecutive trading days, with the company warning of potential rapid declines due to market sentiment and irrational speculation [4] Group 3: Mergers and Acquisitions - Guotai Group announced the acquisition of 100% equity in Beikuan Baomao for 110 million yuan through a public bidding process [3] Group 4: New Projects and Contracts - Lichong Group's subsidiaries received project confirmations for aluminum alloy wheels, with expected total sales of approximately 1.135 billion yuan over the project lifecycles [15] - Anhui Construction's subsidiary won a bid for a project worth 1.753 billion yuan, including two major contracts with a total construction cost of approximately 1.215 billion yuan and 538 million yuan respectively [16] Group 5: Clinical Trials and Innovations - Haishi Science received approval for clinical trials of HSK39297 tablets for age-related macular degeneration, indicating strong development potential and a favorable benefit/risk ratio [6]

Major Events - Guotai Group acquired 100% equity of Beikuan Baomao for 110 million yuan through public bidding [4] - People's Tongtai stock price has a risk of rapid decline after a 46.43% increase over four consecutive trading days [5] - Huasheng Lithium's revenue increased by 62% in the first three quarters, but the company still reported a loss [6][7] - Haishi Ke received approval for clinical trials of a new drug HSK39297 for age-related macular degeneration [8] - Angli Education postponed its response to an asset acquisition inquiry for no more than five trading days [9] - Shuguang Co. terminated its plan to issue shares to specific investors, and the Shanghai Stock Exchange has stopped reviewing the application [10] Performance Overview - JD Group reported third-quarter revenue of 299.1 billion yuan, a year-on-year increase of 14.9% [11] - SMIC's third-quarter net profit reached 1.517 billion yuan, up 43.1% year-on-year [12][13] - Tencent Holdings achieved third-quarter revenue of 192.87 billion yuan, a 15% year-on-year increase [14] - Lu'an Huaneng's coal sales in October were 3.78 million tons, a year-on-year increase of 3.28% [15] Shareholding Changes - Haicheng Bangda's director plans to reduce holdings by no more than 0.97% due to personal financial needs [16] - Qisheng Technology's major shareholder reduced its stake to 40% through a block trade [17] - Tianwei Electronics' major shareholder reduced holdings to below 5% without affecting company operations [18] - Zhongzi Technology's major shareholders collectively reduced their stake by 1.35% [19] Major Contracts - Lizhong Group's subsidiary received project confirmations with an estimated total sales of approximately 1.135 billion yuan [21] - Anhui Construction's subsidiary won a project bid worth 1.753 billion yuan [22]

Major Announcements - Guotai Group acquired 100% equity of Beikuan Baomao for 110 million yuan through public bidding [3] - People's Tongtai stock price has risen for four consecutive trading days, with a total increase of 46.43%, indicating potential rapid decline risk due to market sentiment [4] - Huasheng Lithium's stock price has deviated significantly, with a 62% revenue increase in the first three quarters, but still reporting a net loss of 10.3 million yuan [5] - Haishi Ke received approval for clinical trials of innovative drug HSK39297 for age-related macular degeneration, showing high development potential [6] - Angli Education postponed its response to an asset acquisition inquiry for no more than five trading days [7] - Shuguang Co. terminated its plan to issue shares to specific targets, with the Shanghai Stock Exchange halting the review [8] Performance Overview - JD Group reported third-quarter revenue of 299.1 billion yuan, a year-on-year increase of 14.9%, with net profit of 5.3 billion yuan [10] - SMIC achieved third-quarter net profit of 1.517 billion yuan, a 43.1% year-on-year increase, with revenue of 17.162 billion yuan [11][12] - Tencent Holdings reported third-quarter revenue of 192.87 billion yuan, a 15% year-on-year increase, with operating profit of 72.57 billion yuan [13] - Lu'an Huaneng's coal sales in October reached 3.78 million tons, a year-on-year increase of 3.28% [14] Shareholding Changes - Haicheng Bangda's director Wang Xiping plans to reduce his holdings by up to 0.97% due to personal financial needs [16] - Qisheng Technology's major shareholder reduced their stake to 40% through a block trade [17] - Tianwei Electronics' major shareholder Xie Kai reduced his holdings to below 5% [18] - Zhongzi Technology's major shareholders collectively reduced their stake by 1.35% [19] Major Contracts - Lichong Group's subsidiaries received project confirmations with an estimated total sales of approximately 1.135 billion yuan [21] - Anhui Construction's subsidiary won a project bid worth 1.753 billion yuan [22]

人民财讯11月13日电，海思科（002653）11月13日公告，公司近日收到国家药监局下发的HSK39297片 《药物临床试验批准通知书》，适应症为年龄相关性黄斑变性。HSK39297片是公司自主研发的一个全 新的具有独立知识产权的治疗年龄相关性黄斑变性的药物。临床前研究结果表明，该药品靶点明确、疗 效确切、安全性好，是一款极具开发潜力的小分子药物，临床应用的效益/风险比高，具有广阔的临床 应用前景，有望成为AMD的有效治疗药物，解决目前临床用药匮乏的难题。 ...

Core Viewpoint - The company received approval from the National Medical Products Administration for clinical trials of its innovative drug HSK39297 tablets, aimed at treating age-related macular degeneration, indicating a significant advancement in its product pipeline [1] Group 1: Drug Development - HSK39297 is a tablet formulation specifically targeting age-related macular degeneration [1] - Preclinical studies have shown that HSK39297 has a clear target, confirmed efficacy, and good safety profile, suggesting a high benefit/risk ratio [1] - The drug is expected to offer a more advantageous treatment option compared to existing therapies, which often require frequent injections and do not significantly improve vision [1] Group 2: Market Potential - There are currently limited treatment options available for age-related macular degeneration, highlighting the potential market opportunity for HSK39297 [1] - The approval for clinical trials positions the company favorably within a niche market with significant unmet medical needs [1]

海思科公告称，近日收到国家药监局下发的《药物临床试验批准通知书》，其自主研发的创新药 HSK39297片（片剂）用于年龄相关性黄斑变性的境内生产药品注册临床试验申请获批。2015年我国 AMD患病率约5.2%，患者近2665万人，2040年预计近3亿人患病。目前AMD治疗药物存在局限，该药 物靶点明确、疗效确切、安全性好，有望解决临床用药难题。不过，创新药研发风险高，公司将及时披 露进展。 ...

HSK39297片是公司自主研发的一个全新的具有独立知识产权的治疗年龄相关性黄斑变性的药物。临床 前研究结果表明，本品靶点明确、疗效确切、安全性好，是一款极具开发潜力的小分子药物，临床应用 的效益/风险比高，具有广阔的临床应用前景，有望成为AMD的有效治疗药物，解决目前临床用药匮乏 的难题。 海思科（002653）(002653.SZ)发布公告，公司近日收到国家药品监督管理局下发的《药物临床试验批 准通知书》，经审查，2025年8月受理的HSK39297片临床试验申请符合药品注册的有关要求，同意开展 临床试验。 ...